Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
This target represents an annotated antisense noncoding RNA transcript (ENSG00000289607, LOC105378353) at the SLC29A3 genomic locus. There is currently no published evidence that this transcript produces a functional protein, acts as a direct disease gene, or serves as a drug target or biomarker. Its annotation is based on genomic sequencing and transcript mapping. In contrast, the sense/coding transcript of SLC29A3 encodes equilibrative nucleoside transporter 3 (ENT3), which is involved in nucleoside transport, cellular metabolism, and several inherited multisystem disorders[1][3][4][6]. The antisense transcript described here does not share these functional properties or clinical relevance.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Novel transcript, antisense to SLC29A3 (ENSG00000289607 (LOC105378353)).